Prosecution Insights
Last updated: October 25, 2026

Nguyen Tarbet Ip Law

Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering

63 pending office actions • 28 clients • 63 examiners • 44 art units • 0 of 63 (0%) have an AI response strategy ready • 58 patents granted in the last 365 days

Analysis

NGUYEN TARBET IP Law has 62 pending office actions in Biotechnology & Pharmaceuticals and 2,032 career applications. The profile shows a substantial active life-sciences workload supported by a broad historical application record.

The resolved allowance rate is 73.03%, and the average office actions per allowance is 2.71. Resolved matters reached allowance in a substantial portion of the record, while allowed matters generally involved repeated examination activity.

Practitioners should examine how biological and pharmaceutical claim scope was supported through prosecution, including the use of experimental evidence and responses to written-description, enablement, or prior-art issues. The active docket also calls for prioritization where examination objections may affect commercially important claim sets.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Quality Metrics (n=2032 apps, methodology: how we score firms)

73.0%
Allowance Rate
n=2032
+0.50σ
Allowance Rate (norm)
n=2032
2.7
OAs to Allowance
n=731
-0.57σ
OAs to Allow (norm)
n=731
1001 days
Time to Allowance
n=731
+26.4pp
Interview Lift
n=2032
21.9%
RCE Rate
n=2032
0.5%
Appeal Rate
n=2032

Rejection Performance (% of received rejections ultimately overcome)

61.2%
§101 Overcome
n=116
61.8%
§102 Overcome
n=382
62.2%
§103 Overcome
n=637
63.8%
§112 Overcome
n=528

Specialization & Scale

A61K, G01N, A61B
Top CPC Subclasses
19%
Top-3 CPC Share
n=2032
0
Practitioners
n=2032
—
Apps / Practitioner
n=2032 (min 20)

Portfolio Summary

63
Total Pending OAs
44
Non-Final OAs
19
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 20 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

7
Overdue
1
Due this week
9
Due this month
1
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 20 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (7)Due ≤ 7 days (1)Due ≤ 30 days (9)Due ≤ 60 days (1)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

44
Hard (70%)
15
Medium (24%)
4
Easy (6%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 only3 (5%)
§101 + other6 (10%)
§103 only11 (17%)
§102 only1 (2%)
§112 only4 (6%)
Double-patenting + other3 (5%)
Multi-statute (no §101)35 (56%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

41
Life Sciences
65% of docket
0
Information Tech
0% of docket
1
Communications
2% of docket
4
Semiconductors
6% of docket
17
Mechanical / Eng
27% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

630 h
Manual time on pending OAs
126 h
Time saved (low, 20%)
220 h
Time saved (mid, 35%)
5.5 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
GALSTER, SAMUEL LEONARD 1 52.1% +42.2%
HUYNH, EMILY 1 22.9% +44.9%
GABR, MOHAMED GAMIL 1 80.6% +21.9%
TENTONI, LEO B 1 81.9% +10.1%
DAVIS, DAVID DONALD 1 70.3% +9.6%
JAFFRI, ZEHRA 1 58.0% +49.1%
UTT, ETHAN A 1 48.1% +40.6%
NGUYEN, CHI Q 1 82.4% +12.4%
WILKES, ZACHARY W 1 66.5% +22.5%
ALBERS, KEVIN S 1 25.4% +50.4%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
19096165 TORQUEABLE DEVICES AND METHODS FOR REMOVING AN EMBOLUS GABR, MOHAMED GAMIL —

Hard Cases (44)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17790659 HIGH-SURFACE AREA ELECTRODES FOR WEARABLE ELECTROCHEMICAL BIOSENSING GAITONDE, MEGHA MEHTA 121d overdue
18164368 METHODS AND COMPOSITIONS FOR UPREGULATING RNA INTERFERENCE AND ENHANCING GENE SILENCING SPAINE, ROBERT FRANKLIN 87d overdue
17631653 PHYTO-MEDIATED WASTEWATER TREATMENT BIOREACTOR (PWBR) ROYCE, LIAM A 49d overdue
19275384 VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE GALSTER, SAMUEL LEONARD 10d overdue
18301896 METHOD OF SYNTHESIZING 18F RADIOLABELED BIOMOLECULAR AGENTS DONOHUE, SEAN R 2d overdue
17680636 DEVICE FOR TRANSCATHETER GRABBING AND SECURING A NATIVE MITRAL VALVE LEAFLET TO A PROSTHESIS BLASS, PARIS MARIE 15d
17496391 METHODS AND SYSTEMS FOR IMPROVING CELLS FOR USE IN THERAPY KIM, TAEYOON 19d
18174158 METHODS, SYSTEMS, AND COMPOSITIONS FOR LEGUME-BASED PRODUCTION OF THERAPEUTIC PROTEINS AND THERAPEUTIC MEDICAL MATERIALS HA, JULIE 22d

Interview Candidates (9)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
19275384 VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE GALSTER, SAMUEL LEONARD 10d overdue
18973590 BRACING DEVICE FOR RESTORING NATURAL FOOT MOVEMENT TO FLAT FOOT DEFORMITY PATIENTS ALBERS, KEVIN S 27d
19192052 MENOPAUSE PREDICTING TOOL HUYNH, EMILY —
19096165 TORQUEABLE DEVICES AND METHODS FOR REMOVING AN EMBOLUS GABR, MOHAMED GAMIL —
19081965 ECO-FRIENDLY, SUSTAINABLE, LIGHTWEIGHT, POROUS CELLULOSE SPONGE FOR CROP GROWTH TENTONI, LEO B —
19009323 SYSTEMS AND METHODS FOR REDUCTION AND FIXATION OF FRACTURES AND TISSUES JAFFRI, ZEHRA —
19001051 CHEMICAL RESISTANT POLYMER CONCRETE AND METHODS OF USE THEREOF UTT, ETHAN A —
19000986 STRUCTURAL ELEMENT REINFORCEMENT SYSTEMS AND METHODS NGUYEN, CHI Q —

Client Portfolio (28 clients)

Top Art Units

Art UnitApps
37914
16784
37713
16543
16183
16753
17582
16322
16812
37622

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
19275384 VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE Bio-Synthesis, Inc. GALSTER, SAMUEL LEONARD 1693 §103§112 Final Rejection 10d overdue Pending Jul 21, 2025
19192052 MENOPAUSE PREDICTING TOOL Timeless Biotech Incorporated HUYNH, EMILY 3683 §101 Non-Final OA — Pending Apr 28, 2025
19096165 TORQUEABLE DEVICES AND METHODS FOR REMOVING AN EMBOLUS Innova Vascular, Inc. GABR, MOHAMED GAMIL 3771 §103 Non-Final OA — Pending Mar 31, 2025
19081965 ECO-FRIENDLY, SUSTAINABLE, LIGHTWEIGHT, POROUS CELLULOSE SPONGE FOR CROP GROWTH Arizona Board of Regents TENTONI, LEO B 1742 §102§103 Non-Final OA — Pending Mar 17, 2025
19062526 INCONTINENCE DETECTION DEVICE Mad Bladder, Inc. DAVIS, DAVID DONALD 2627 §102§112 Non-Final OA — Pending Feb 25, 2025
19009323 SYSTEMS AND METHODS FOR REDUCTION AND FIXATION OF FRACTURES AND TISSUES Primo Medical Group JAFFRI, ZEHRA 3771 §102§103§112 Non-Final OA — Pending Jan 03, 2025
19001051 CHEMICAL RESISTANT POLYMER CONCRETE AND METHODS OF USE THEREOF Composite Construction, LLC UTT, ETHAN A 1783 §102§103§112Other Non-Final OA — Pending Dec 24, 2024
19000986 STRUCTURAL ELEMENT REINFORCEMENT SYSTEMS AND METHODS Carboshield, Inc. NGUYEN, CHI Q 3635 §102§103§112Other Non-Final OA — Pending Dec 24, 2024
18999085 DOG BONE SHAPED CYLINDRICAL TUNABLE FLUIDIC LENS WITH MINIMIZED DEFOCUS Icrx, Inc. WILKES, ZACHARY W 2872 §102§112DP Non-Final OA — Pending Dec 23, 2024
18973590 BRACING DEVICE FOR RESTORING NATURAL FOOT MOVEMENT TO FLAT FOOT DEFORMITY PATIENTS Arizona Board of Regents ALBERS, KEVIN S 3786 §102§103§112 Final Rejection 27d Pending Dec 09, 2024
18974619 HYBRID FLU-CORONAVIRUS VACCINE The Regents of the University of California ALLEN, MICHAEL D 1671 §102§103§112DP Non-Final OA — Pending Dec 09, 2024
18922821 MODULAR FLOW CYTOMETRY SYSTEMS AND METHODS OF PROCESSING SAMPLES Abs Global, Inc. HUANG, MICKEY NMN 1758 §102§103§112 Non-Final OA — Pending Oct 22, 2024
18921500 FILTER DEVICE FOR HUMAN BLOOD REINFUSION Innova Vascular, Inc. NGUYEN, BOI-LIEN THI 1779 §103§112 Non-Final OA — Pending Oct 21, 2024
18899395 METHODS OF TREATMENT UTILIZING CANINE-SPECIFIC THERAPEUTIC COMPOSITIONS Alphalogix, LLC EBBINGHAUS, BRIANA NOEL 1632 §102§112 Non-Final OA — Pending Sep 27, 2024
18896702 MAGNETIC STENT SYSTEM FOR PREVENTION OF STENT MIGRATION The Regents of the University of California EREZO, DARWIN P 3771 §101§102 Non-Final OA — Pending Sep 25, 2024
18844645 CALCIMYCIN AS ANTIFUNGALS Arizona Board of Regents REILLY, SOPHIA JANE 1627 §103Other Non-Final OA — Pending Sep 06, 2024
18824184 METHODS FOR TREATING POLYMICROBIAL INFECTIONS Cap Diagnostics, LLC Dba Pathnostics FERNANDEZ, SUSAN EMILY 1651 §102§103 Non-Final OA — Pending Sep 04, 2024
18807571 METHODS AND SYSTEMS FOR DETERMINING SUITABILITY OF COMPOSITIONS FOR INHIBITING GROWTH OF POLYMICROBIAL SAMPLES Cap Diagnostics, LLC Dba Pathnostics OYEYEMI, OLAYINKA A 1681 §103§112 Non-Final OA — Pending Aug 16, 2024
18804611 INTRA-BEAT BIOMARKER FOR ACCURATE BLOOD PRESSURE ESTIMATIONS The Regents of the University of California TOMBERS, JOSEPH A 3791 §101§102§103 Non-Final OA — Pending Aug 14, 2024
18770157 METHOD OF CREATING BIOCOMPATIBLE POLYMERIC RESIN SYSTEMS FOR BONE REPAIR AND MANAGEMENT Medicarbone, Inc. PEPITONE, MICHAEL F 1767 §103§112Other Non-Final OA — Pending Jul 11, 2024
18754715 METHODS FOR THE PROGNOSIS AND TREATMENT OF TEMPORAL LOBE EPILEPSY Arizona Board of Regents PRIEST, AARON A 1681 §101§112 Non-Final OA — Pending Jun 26, 2024
18724159 SOLAR HOT AIR BALLOON VENT Arizona Board of Regents XAVIER, VALENTINA 3642 §103 Final Rejection 14d Pending Jun 25, 2024
18669370 METHODS AND SYSTEMS FOR DETECTING URINARY TRACT INFECTIONS Cap Diagnostics, LLC Dba Pathnostics HAQ, SHAFIQUL 1678 §101§103 Non-Final OA — Pending May 20, 2024
18667395 ANORECTAL TONOMETER FOR NEUROLOGICAL TESTING Arizona Board of Regents BERHANU, ETSUB D 3791 §103§112 Final Rejection — Pending May 17, 2024
18694638 VENTILATION DEMAND CONTROL Tamworth Corporation Limited FAULKNER, RYAN L 3762 §102§103§112 Non-Final OA — Pending Mar 22, 2024
18606835 COMPOSITE REINFORCEMENT OF TUBULAR STRUCTURES Carboshield, Inc. DEAL, DAVID R 3753 §102§103Other Non-Final OA — Pending Mar 15, 2024
18601656 ELECTROCHEMICAL, APTAMER-BASED POINT-OF-CARE CEREBROSPINAL FLUID DETECTION The Regents of the University of California NOGUEROLA, ALEXANDER STEPHAN 1795 §112 Non-Final OA — Pending Mar 11, 2024
18594328 DIELECTRIC WAVEGUIDE ANTENNA ARRAY Electronic Design & Development, Corp. HAMMOND, CRYSTAL L 2838 §102 Non-Final OA 84d Pending Mar 04, 2024
18586133 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LUNG DISEASE Raesedo, LLC MARTINEZ, TARA L 1654 §112 Non-Final OA — Pending Feb 23, 2024
18684808 QUINACRINE AND DERIVATIVES THEREOF FOR TREATMENT OF VIRAL INFECTIONS Arizona Board of Regents LEE, WILLIAM Y 1626 §102§103§112 Non-Final OA — Pending Feb 19, 2024
18579127 ADDITIVE MANUFACTURING OF TUNABLE POLYMERIC 3D ARCHITECTURES FOR MULTIFUNCTIONAL APPLICATIONS The Regents of the University of California MALIK, VIPUL 1744 §102§103§112 Non-Final OA — Pending Jan 12, 2024
18391302 ENZYME-LINKED IMMUNOSORBENT SENSOR ("ELIS-S") Phagetech, Inc. QIAN, SHIZHI 1700 §102§103§112 Non-Final OA — Pending Dec 20, 2023
18566935 BENCH-STABLE TRIAZENE COMPOSITIONS FOR PROTEIN MODIFICATION Arizona Board of Regents ROGERS, JAMES WILLIAM 1618 §102§112Other Non-Final OA — Pending Dec 04, 2023
18566564 METHODS AND COMPOSITIONS FOR LOCALIZATION OF GROWTH FACTORS The United States Department of Veterans Affairs BERHANE, SELAM 1675 §103§112 Non-Final OA — Pending Dec 01, 2023
18487608 INDIUM OXIDE NANORODS, METHODS FOR PREPARING AND USING SAME Yangtze Delta Region Institute (Huzhou), University Of Electronic Science And Technology Of China KESSEL, MARIS R 1758 §102§103§112 Non-Final OA — Pending Oct 16, 2023
18553953 ELIMINATION OF AFLATOXIN VIA AFLATOXIN-DEGRADING ENZYME EXPRESSION IN CROPS Arizona Board of Regents CHATTERJEE, JAYANTA 1662 §103§112DP Final Rejection — Pending Oct 04, 2023
18552959 SPRAYABLE COOL WHITE COATING BASED ON CERAMIC MICROSPHERES The Regents of the University of California LIOTT, CAROLINE DUSHECK 1732 §103§112 Final Rejection — Pending Sep 28, 2023
18549335 DEVELOPMENT OF APTAMERS FOR NEUTRALIZING ANTIBODIES IN DEMYELINATING DISEASES Arizona Board of Regents JOHNSON, TIRONE DEREK 1675 §102§103§112 Non-Final OA — Pending Sep 06, 2023
18337375 RADIONUCLIDE BRACHYTHERAPY SOURCE SYSTEMS FOR APPLICATION OF BETA RADIATION Illinois Tool Works Inc. LANNU, JOSHUA DARYL DEANON 3791 §102§103§112 Non-Final OA — Pending Jun 19, 2023
18323667 ENGINEERED NEOCARTILAGE TISSUE COMPOSITIONS The Regents of the University of California CORDAS, EMILY ANN 1632 §103 Final Rejection — Pending May 25, 2023
18308239 GROWTH-ACCOMMODATING VALVE SYSTEM The Regents of the University of California WOZNICKI, JACQUELINE 3774 §102§103§112 Final Rejection — Pending Apr 27, 2023
18301896 METHOD OF SYNTHESIZING 18F RADIOLABELED BIOMOLECULAR AGENTS Theracea Pharma, LC DONOHUE, SEAN R 1618 §103§112 Final Rejection 2d overdue Pending Apr 17, 2023
18246636 DEVICES AND RELATED METHODS FOR PHYSIOLOGICAL EXAMINATION The Regents of the University of California BRUCE, FAROUK A 3797 §103 Non-Final OA 28d Pending Mar 24, 2023
18044344 BIOSENSOR FOR DETECTING STRUCTURAL CHANGES IN HUMAN CARDIAC MUSCLE PROTEIN Arizona Board of Regents IVICH, FERNANDO NMN 1678 §102§103§112 Final Rejection — Pending Mar 07, 2023
18043694 SOLAR TOWER TO DRY ORGANIC MATTER ON A LARGE SCALE Arizona Board of Regents LAU, JASON 3762 §103 Non-Final OA 70d Pending Mar 01, 2023
18174158 METHODS, SYSTEMS, AND COMPOSITIONS FOR LEGUME-BASED PRODUCTION OF THERAPEUTIC PROTEINS AND THERAPEUTIC MEDICAL MATERIALS Arizona Board of Regents HA, JULIE 1654 §101§102§103§112 Non-Final OA 22d Pending Feb 24, 2023
18169646 ASPIRATION ENDOSCOPE DEVICE AND METHODS OF USE THEREOF The Regents of the University of California HENSON, DEVIN B 3791 §103 Final Rejection 15d Pending Feb 15, 2023
18166390 METHODS AND COMPOSITION FOR DYE-BASED ENCODING AND QUANTIFICATION Arizona Board of Regents WESTERBERG, NISSA M 1618 §102§103 Final Rejection 33d Pending Feb 08, 2023
18164368 METHODS AND COMPOSITIONS FOR UPREGULATING RNA INTERFERENCE AND ENHANCING GENE SILENCING Gowey Research Group, Pllc SPAINE, ROBERT FRANKLIN 1655 §103§112 Non-Final OA 87d overdue Pending Feb 03, 2023
18006110 ECHINOCANDIN DRUG IMPURITY, AND PREPARATION AND PURIFICATION METHODS AND USE THEREOF Shanghai Techwell Biopharmaceutical Co., Ltd. D' AMBROSIO, THEA 1654 §112 Final Rejection 5d Pending Jan 19, 2023

View all 63 →

Managing Nguyen Tarbet Ip Law's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

What is Nguyen Tarbet Ip Law's patent allowance rate?

73.0% of resolved applications prosecuted by Nguyen Tarbet Ip Law were allowed, across 2,032 applications in USPTO records.

How many office actions does Nguyen Tarbet Ip Law average before allowance?

2.71 office actions per allowed application on average.

How many pending office actions does Nguyen Tarbet Ip Law have?

63 pending office actions as of October 2026, for 28 clients, before 63 examiners in 44 art units.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month